TUMOUR CAVITATION

This adverse event was reported 55 times

These drugs are most commonly taken by patients reporting TUMOUR CAVITATION:

# Drug Count
0 CARBOPLATIN 16
1 PACLITAXEL 16
2 BEVACIZUMAB 11
3 RAMUCIRUMAB 9
4 DOCETAXEL 7
5 DOCETAXEL ANHYDROUS 7
6 NIVOLUMAB 6
7 REGORAFENIB 5
8 PAZOPANIB HYDROCHLORIDE 4
9 CYCLOPHOSPHAMIDE 3
See all common drugs associated with TUMOUR CAVITATION

TUMOUR CAVITATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 RAMUCIRUMAB 9 0.0014
1 NALDEMEDINE 1 0.0006
2 REGORAFENIB 5 0.0004
3 LEMBOREXANT 1 0.0003
4 AMIVANTAMAB-VMJW 1 0.0003
5 VONOPRAZAN FUMARATE 2 0.0002
6 PACLITAXEL 16 0.0002
7 AFATINIB 1 0.0002
8 PAZOPANIB HYDROCHLORIDE 4 0.0001
9 ENFORTUMAB VEDOTIN 1 0.0001
See all drugs enriched for association with TUMOUR CAVITATION